HRP20191402T1 - Piridil hidrazona za liječenje tuberkuloze i srodnih bolesti - Google Patents
Piridil hidrazona za liječenje tuberkuloze i srodnih bolesti Download PDFInfo
- Publication number
- HRP20191402T1 HRP20191402T1 HRP20191402T HRP20191402T1 HR P20191402 T1 HRP20191402 T1 HR P20191402T1 HR P20191402 T HRP20191402 T HR P20191402T HR P20191402 T1 HRP20191402 T1 HR P20191402T1
- Authority
- HR
- Croatia
- Prior art keywords
- mycobacterium
- use according
- pharmaceutical preparation
- tuberculosis
- pharmaceutically acceptable
- Prior art date
Links
- 201000008827 tuberculosis Diseases 0.000 title claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 2
- -1 Pyridyl hydrazones Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 9
- 206010062207 Mycobacterial infection Diseases 0.000 claims 5
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 5
- 208000027531 mycobacterial infectious disease Diseases 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 2
- 241000186362 Mycobacterium leprae Species 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 241000186359 Mycobacterium Species 0.000 claims 1
- 241001508003 Mycobacterium abscessus Species 0.000 claims 1
- 241001467553 Mycobacterium africanum Species 0.000 claims 1
- 241000186367 Mycobacterium avium Species 0.000 claims 1
- 241000513886 Mycobacterium avium complex (MAC) Species 0.000 claims 1
- 241000186366 Mycobacterium bovis Species 0.000 claims 1
- 241000187478 Mycobacterium chelonae Species 0.000 claims 1
- 241000186365 Mycobacterium fortuitum Species 0.000 claims 1
- 241000187484 Mycobacterium gordonae Species 0.000 claims 1
- 241000186364 Mycobacterium intracellulare Species 0.000 claims 1
- 241000186363 Mycobacterium kansasii Species 0.000 claims 1
- 241001248583 Mycobacterium lentiflavum Species 0.000 claims 1
- 241000187492 Mycobacterium marinum Species 0.000 claims 1
- 241000187919 Mycobacterium microti Species 0.000 claims 1
- 241000187490 Mycobacterium scrofulaceum Species 0.000 claims 1
- 241000187480 Mycobacterium smegmatis Species 0.000 claims 1
- 241000187495 Mycobacterium terrae Species 0.000 claims 1
- 241000187644 Mycobacterium vaccae Species 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000006196 drop Substances 0.000 claims 1
- 201000006674 extrapulmonary tuberculosis Diseases 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical group 0.000 claims 1
- 239000007902 hard capsule Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- RMIODHQZRUFFFF-UHFFFAOYSA-N methoxyacetic acid Chemical group COCC(O)=O RMIODHQZRUFFFF-UHFFFAOYSA-N 0.000 claims 1
- 239000003094 microcapsule Substances 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000007901 soft capsule Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
- C07D213/77—Hydrazine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (11)
1. Spoj opće formule (Ia)
za uporabu u liječenju i/ili prevenciji mikobakterijskih infekcija uzrokovanih, netuberkuloznim mikobakterijama (NTM), Mycobacterium leprae, i multirezistentnom Mycobacterium tuberculosis,
naznačeno time da
R1, R2 i R3 su svaki međusobno neovisno, vodik, (C1-C4)alkil, hidroksil, halogen, metoksi ili metoksioctena kiselina
ili njihova farmaceutski prihvatljiva sol, ester ili solvat.
2. Spoj za uporabu sukladno patentnom zahtjevu 1, odabrano iz skupine sastavljene od N-piridin-2-yl-N’-3,5-dibromo-2-hidroksifenilmetilen-hidrazin, N-piridin-2-yl-N’-5-metil-2-hidroksifenilmetilen-hidrazin i (E)-2 ili njihove farmaceutski prihvatljive soli, estera ili solvata.
3. Spoj za uporabu sukladno bilo kod od patentnih zahtjeva 1 i 2 naznačen time da je u obliku farmaceutski prihvatljive soli, estera ili solvata.
4. Farmaceutski pripravak za uporabu u liječenju i/ili prevenciji mikobakterijskih infekcija uzrokovanih, netuberkuloznim mikobakterijama (NTM) Mycobacterium leprae, i multirezistentnom Mycobacterium tuberculosis naznačeno time da sadrži najmanje spoj Formule (Ia) kao što je definirano u bilo kojem od patentnih zahtjeva 1 do 3, ili njegova farmaceutski prihvatljiva sol, ester ili solvat i najmanje farmaceutski prihvatljiv ekscipijent.
5. Farmaceutski pripravak za uporabu sukladno patentnom zahtjevu 4, za mikobakterijske infekcije uzrokovane multirezistentnom Mycobacterium tuberculosis odabran iz skupine sastavljene od primarne tuberkulozne bolesti, post-primarne pleuropulmonalne tuberkulozne bolesti, post-primarne ekstra-pulmonalne tuberkulozne bolesti uključujući najmanje jedan organ ili sustav sisavaca.
6. Farmaceutski pripravak za uporabu sukladno patentnom zahtjevu 5, za mikobakterijalne infekcije uzrokovane multirezistentnom Mycobacterium tuberculosis uključujući infekciju uzrokovanu organizmima iz skupine odabrane iz Mycobacterium tuberculosis (Mtb), Mycobacterium bovis, Mycobacterium africanum, Mycobacterium canetii i Mycobacterium microti.
7. Farmaceutski pripravak za uporabu sukladno patentnom zahtjevu 4, za mikobakterijalne infekcije uzrokovane netuberkuloznim mikobakterijama (NTM) uključuju infekciju uzrokovane organizmima iz skupine odabrane iz Mycobacterium avium kompleksa (MaC), Mycobacterium smegmatis, Mycobacterium gordonae, Mycobacterium kansasii, Mycobacterium terrae, Mycobacterium scrofulaceum, Mycobacterium vaccae, Mycobacterium marinum, Mycobacterium lentiflavum, Mycobacterium fortuitum, Mycobacterium chelonae, Mycobacterium abscessus, Mycobacterium intracellulare i Mycobacterium avium.
8. Farmaceutski pripravak za uporabu sukladno bilo kojem od patentnih zahtjeva 4 do 7, naznačeno time da su liječene skupine djeca ili stariji pacijenti.
9. Farmaceutski pripravak za uporabu sukladno bilo kojem od patentnih zahtjeva 4 do 7, naznačeno time da su liječene skupine pacijenti s bilo kojim imunosupresivnim stanjem.
10. Farmaceutski pripravak za uporabu sukladno bilo kojem od patentnih zahtjeva 4 do 9, naznačeno time da je pripravak u obliku tablete, obložene tablete, mikrokapsule, meke kapsule, tvrde kapsule, peleta, supozitorije, praška, otopine, suspenzije, aerosola, sirupa, kapi, krema, paste, gela, masti, tinkture, stika za usne i/ili spreja.
11. Farmaceutski pripravak za uporabu sukladno bilo kojem od patentnih zahtjeva 4 do 10, naznačeno time da liječenje sadrži primjenu farmaceutskog pripravka na sisavca u dnevnoj dozi od između 0.01mg/po kg tjelesne težine 5000mg/kg tjelesne težine.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PT106652A PT106652A (pt) | 2012-11-20 | 2012-11-20 | Piridil hidrazonas para o tratamento de tuberculose e doenças relacionadas |
| EP13811632.2A EP2922541B1 (en) | 2012-11-20 | 2013-11-20 | Pyridyl hydrazones for the treatment of tuberculosis and related diseases |
| PCT/PT2013/000068 WO2014081324A1 (en) | 2012-11-20 | 2013-11-20 | Pyridyl hydrazones for the treatment of tuberculosis and related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191402T1 true HRP20191402T1 (hr) | 2019-11-15 |
Family
ID=49876952
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211767TT HRP20211767T1 (hr) | 2012-11-20 | 2013-11-20 | Piridil hidrazoni za liječenje tuberkuloze i povezanih bolesti |
| HRP20191402 HRP20191402T1 (hr) | 2012-11-20 | 2019-08-02 | Piridil hidrazona za liječenje tuberkuloze i srodnih bolesti |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211767TT HRP20211767T1 (hr) | 2012-11-20 | 2013-11-20 | Piridil hidrazoni za liječenje tuberkuloze i povezanih bolesti |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9593103B2 (hr) |
| EP (2) | EP2922541B1 (hr) |
| BR (1) | BR112015011606A2 (hr) |
| CY (2) | CY1121861T1 (hr) |
| DK (1) | DK2922541T3 (hr) |
| ES (2) | ES2899437T3 (hr) |
| HR (2) | HRP20211767T1 (hr) |
| HU (2) | HUE056531T2 (hr) |
| LT (2) | LT3539543T (hr) |
| MA (1) | MA38206B1 (hr) |
| PL (2) | PL3539543T3 (hr) |
| PT (3) | PT106652A (hr) |
| RS (2) | RS62579B1 (hr) |
| SI (2) | SI3539543T1 (hr) |
| WO (1) | WO2014081324A1 (hr) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3716131A1 (de) * | 1987-05-14 | 1988-12-01 | Forsch Borstel Inst Fuer Exper | Substituierte 2-acylpyridin-(alpha)-(n)-hetarylhydrazone sowie diese enthaltende arzneimittel |
| US8865901B2 (en) * | 2009-10-02 | 2014-10-21 | Fred Hutchinson Cancer Research Center | Gain-of-function Bcl-2 inhibitors |
| EP2311457A1 (en) * | 2009-10-19 | 2011-04-20 | Forschungszentrum Borstel | Pharmaceutical compositions for treating infections with drug resistant mycobacteria |
-
2012
- 2012-11-20 PT PT106652A patent/PT106652A/pt unknown
-
2013
- 2013-11-20 PL PL19167996T patent/PL3539543T3/pl unknown
- 2013-11-20 LT LTEP19167996.8T patent/LT3539543T/lt unknown
- 2013-11-20 HU HUE19167996A patent/HUE056531T2/hu unknown
- 2013-11-20 LT LTEP13811632.2T patent/LT2922541T/lt unknown
- 2013-11-20 ES ES19167996T patent/ES2899437T3/es active Active
- 2013-11-20 HR HRP20211767TT patent/HRP20211767T1/hr unknown
- 2013-11-20 PT PT191679968T patent/PT3539543T/pt unknown
- 2013-11-20 RS RS20211433A patent/RS62579B1/sr unknown
- 2013-11-20 DK DK13811632.2T patent/DK2922541T3/da active
- 2013-11-20 ES ES13811632T patent/ES2741434T3/es active Active
- 2013-11-20 EP EP13811632.2A patent/EP2922541B1/en active Active
- 2013-11-20 SI SI201331949T patent/SI3539543T1/sl unknown
- 2013-11-20 SI SI201331543T patent/SI2922541T1/sl unknown
- 2013-11-20 US US14/646,197 patent/US9593103B2/en active Active
- 2013-11-20 EP EP19167996.8A patent/EP3539543B1/en active Active
- 2013-11-20 RS RSP20191006 patent/RS59224B1/sr unknown
- 2013-11-20 PT PT13811632T patent/PT2922541T/pt unknown
- 2013-11-20 PL PL13811632T patent/PL2922541T3/pl unknown
- 2013-11-20 WO PCT/PT2013/000068 patent/WO2014081324A1/en active Application Filing
- 2013-11-20 BR BR112015011606A patent/BR112015011606A2/pt not_active Application Discontinuation
- 2013-11-20 MA MA38206A patent/MA38206B1/fr unknown
- 2013-11-20 HU HUE13811632A patent/HUE045502T2/hu unknown
-
2019
- 2019-08-02 HR HRP20191402 patent/HRP20191402T1/hr unknown
- 2019-08-06 CY CY20191100833T patent/CY1121861T1/el unknown
-
2021
- 2021-11-26 CY CY20211101030T patent/CY1124836T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI2922541T1 (sl) | 2019-10-30 |
| PL2922541T3 (pl) | 2019-10-31 |
| US9593103B2 (en) | 2017-03-14 |
| ES2741434T3 (es) | 2020-02-11 |
| LT2922541T (lt) | 2019-09-25 |
| MA38206B1 (fr) | 2019-03-29 |
| EP3539543B1 (en) | 2021-09-01 |
| PT106652A (pt) | 2014-05-20 |
| SI3539543T1 (sl) | 2022-01-31 |
| DK2922541T3 (da) | 2019-08-12 |
| CY1121861T1 (el) | 2020-07-31 |
| RS59224B1 (sr) | 2019-10-31 |
| MA38206A1 (fr) | 2017-12-29 |
| EP2922541B1 (en) | 2019-05-22 |
| PL3539543T3 (pl) | 2022-01-10 |
| US20150284374A1 (en) | 2015-10-08 |
| CY1124836T1 (el) | 2022-11-25 |
| LT3539543T (lt) | 2021-12-27 |
| ES2899437T3 (es) | 2022-03-11 |
| RS62579B1 (sr) | 2021-12-31 |
| PT3539543T (pt) | 2021-11-22 |
| HRP20211767T1 (hr) | 2022-02-18 |
| WO2014081324A1 (en) | 2014-05-30 |
| PT2922541T (pt) | 2019-08-26 |
| BR112015011606A2 (pt) | 2017-07-11 |
| EP2922541A1 (en) | 2015-09-30 |
| HUE045502T2 (hu) | 2019-12-30 |
| HUE056531T2 (hu) | 2022-02-28 |
| EP3539543A1 (en) | 2019-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Beena et al. | Antituberculosis drug research: a critical overview | |
| Franz et al. | Design, synthesis and evaluation of indole-2-carboxamides with pan anti-mycobacterial activity | |
| ME00131B (me) | Derivati hinolina i njihova upotreba kao mikobakterijskih inhibitora | |
| US8912329B2 (en) | Composition for treatment of tuberculosis | |
| EA200800455A1 (ru) | Антибактериальные производные хинолина | |
| KR101751930B1 (ko) | 결핵균 또는 비결핵항산균 감염 질환 치료용 약학 조성물 | |
| US20190307760A1 (en) | Acc inhibitors for use in treating mycobacterial diseases | |
| HRP20191402T1 (hr) | Piridil hidrazona za liječenje tuberkuloze i srodnih bolesti | |
| Almeida et al. | Revisiting anti-tuberculosis activity of pyrazinamide in mice | |
| AU2017237380B2 (en) | Antituberculosis agent | |
| WO2016067009A1 (en) | Compounds with activity against bacteria and mycobacteria | |
| V Patel et al. | Nitroimidazoles, quinolones and oxazolidinones as fluorine bearing antitubercular clinical candidates | |
| CN110869016B (zh) | 用于治疗分枝杆菌感染的山费培南或其盐或酯 | |
| US10752621B2 (en) | Oxazolidinone compounds and methods of use thereof as antibacterial agents | |
| JP2015510517A5 (hr) | ||
| Taveira et al. | Preparation and antitubercular activities of alkylated amino alcohols and their glycosylated derivatives | |
| KR101401869B1 (ko) | 에스트로젠의 마이코박테리아 균주 감염 억제용 용도 | |
| Rogoza et al. | Natural and synthetic compounds with an antimycobacterial activity | |
| Moodley | Evaluation of the MTT and MABA assays for rapid screening of the in vitro activity of synthetic chalcones against Mycobacterium tuberculosis. | |
| Laumaillé et al. | Synthesis and study of new antitubercular compounds | |
| CN103896958A (zh) | 冬凌草甲素及其ent-6,7-开环贝壳杉烯型衍生物在制备抗结核药物方面的用途 | |
| Sharma et al. | Chemistry & Biology Interface | |
| RU2018118090A (ru) | Оксазолидиноновые соединения и способы их применения в качестве противобактериальных средств | |
| WO2017142324A3 (ko) | 다중치환 4H-티아졸로[4,5-e][1,4]다이아제핀-5,8-다이온 유도체 및 이의 용도 | |
| Mohammad Asif | Tuberculosis: treatment-related problems and future facets. |